Investigation on Predictive Molecular Markers of Efficacy for Front-line Immunochemotherapy in Advanced NSCLC

Inclusion Criteria: 1. Patients who are clinically diagnosed with stage IV NSCLC; 2. Patients who submitted samples for molecular testing using the OncoScreen Plus panel and PD-L1 (22C3) immunohistochemistry test at baseline; 3. Patients with negative results for sensitizing mutations for 6 genes, including EGFR, ALK, ROS1, BRAF, MET exon 14 skipping, and RET; 4. Patients without contraindications for immunotherapy; 5. Patients who are 18 years or older at the time of signing the informed consent form; 6. Patients with life expectancy of at least 12 weeks; 7. Patients with ECOG score of 0 or 1; 8. Patients with adequate organ function defined by the following criteria: 1. Absolute neutrophil count ≥ 1.5109/L; 2. Platelets ≥ 90109/L; 3. Hemoglobin ≥ 9.0g/dL; 4. Albumin levels ≥2.8 g/L; 5. Total serum bilirubin ≤ 1.5 the upper limit of normal (ULN); for patients with liver metastases, total bilirubin ≤ 2 ULN; 6. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN; for patients with liver metastases, ALT and AST ≤ 5ULN; 7. Serum creatinine ≤ 1.5 ULN; 8. International normalized ratio (INR) or plasma prothrombin time (PT) ≤1.5ULN. Exclusion Criteria: 1. Patients with other concurrent tumors; 2. Patients with other concurrent medical conditions that may affect their follow-up and short-term survival; 3. Patients with any history of immunotherapy; 4. Patients with any history of chemotherapy, radiotherapy or other anti-tumor treatments; 5. Patients with heart function classified as New York Heart Association (NYHA) class III or IV; 6. Patients with peripheral nerve disease; 7. Patients with confirmed hearing loss; 8. Patients with other conditions deemed unsuitable for enrollment by the researchers.